All In Biotech

Drug Trial Radar · NCT07473154

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Phase I/II Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA).

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Apr 10, 2026

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Quell Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1/2, open-label clinical trial to test an experimental treatment called QEL-005 in adults with two autoimmune conditions: diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid arthritis (D2TRA). The main goals are to find out whether QEL-005 is safe, how well people tolerate it, and whether it may help reduce disease activity or improve symptoms. QEL-005 is made from a participant's own white blood cells (autologous cells). These cells are collected and then changed in a laboratory using genetic methods to create specialized immune cells called CAR-T regulatory cells that target a protein on B cells called CD19. These modified cells are then given back to the participant by intravenous (IV) infusion. To take part, eligible participants will first have a procedure called leukapheresis, where some of their white blood cells are removed from the blood. The study team will use these cells to manufacture QEL005. After QEL005 is ready, participants will receive an IV infusion of their modified cells, stay in hospital overnight for monitoring, and will then be followed closely in the clinic. Throughout the trial, participants will have regular safety checks, which may include blood tests, imaging scans, questionnaires about symptoms and daily functioning, and biopsies taken from involved tissues, to help understand how QEL005 is working in the body. Detailed follow up will be for 1 year after QEL-005 infusion, and there is long-term follow up for a total of 15 years, which is standard for cell therapies. The information from this Phase 1/2 study will help determine an appropriate dose and dosing schedule of QEL005 for future studies.

Conditions

  • Diffuse Cutaneous Systemic Sclerosis
  • Rheumatoid Arthritis (RA)
  • Systemic Sclerosis (SSc)
  • Autoimmune Rheumatologic Disease

Interventions

  • QEL-005Drug

    QEL-005 is an autologous cell therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against the B cell marker CD19. Treatment will be given via an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. D2TRA & SSc: Incidence of Protocol-Defined Dose Limiting Toxicities (DLTs) to Assess Safety and Tolerability (Dose Escalation Phase Only)Time frame: up to 28 days post-infusion
  2. D2TRA & SSc: Incidence and grade of treatment-emergent adverse events (TEAEs), adverse events (AEs) and adverse events of special interest (AESIs)Time frame: From time of signing the informed consent form (ICF) through to week 52
  3. D2TRA & SSc: Incidence of clinically significant abnormalities in safety laboratory parameters, electrocardiogram (ECG) findings, and vital signsTime frame: Up to week 52

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • University Hospital Düsseldorf

    Düsseldorf, Germany · Recruiting

  • Universitätsklinikum Erlangen

    Erlangen, Germany · Not yet recruiting

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom · Recruiting

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom · Recruiting

  • Guy's & St Thomas NHS Foundation Trust

    London, United Kingdom · Not yet recruiting

  • Royal Free London NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Manchester University NHS Foundation Trust

    Manchester, United Kingdom · Not yet recruiting

  • Newcastle Upon Tyne NHS Foundation Trust

    Newcastle, United Kingdom · Recruiting

  • University of Oxford - The Kennedy Institute

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.